ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SYN818

A development code. Also written as “SYN818 and Olaparib will be administered”.

Its studies are mostly in Neoplasm Metastasis, led by Hangzhou SynRx Therapeutics Biomedical Technology.

Furthest: phase 1, since Oct 29, 20242 company-led studies, 2 open or runningNext primary completion: Aug 25, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou SynRx Therapeutics Biomedical Technology22 open or runningphase 1since Oct 29, 2024Oct 29, 2024Aug 25, 2028phase 1 · NCT07156253

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2024First study: phase 1 study in Neoplasm MetastasisFirst studyNCT06666270 · 30 planned · China
  2. Aug 27, 2025Phase 1 study in Neoplasm MetastasisNCT07156253 · 110 planned · China

Ahead

  1. Aug 25, 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT07156253

TargetBeta

POLQ →read by rule
“A First-in-human, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of SYN818, a DNA Polymerase Theta (POLQ) Inhibitor Alone in Patients With Locally Advanced or Metastatic Solid Tumors”study text, by rule · the study

Other programs on POLQ

ProgramCompanyFurthest phaseStudies
Polymerase Theta Helicase Inhibitor AZD4956AstraZenecaphase 21

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07156253Neoplasm Metastasis · China1RecruitingAug 25, 2028110
NCT06666270Neoplasm Metastasis · China1RecruitingJun 30, 202630

How it is read

Names in the registry

  • “SYN818 and Olaparib will be administered”, 1 entry
  • “SYN818”, 1 entry

Codes read as this program: SYN818.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.